UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000025972
Receipt No. R000029855
Scientific Title Phase II study of ramucirumab plus docetaxel plus pegfilgrastim with stage IV non-small cell lung cancer patients
Date of disclosure of the study information 2017/02/10
Last modified on 2019/08/06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Phase II study of ramucirumab plus docetaxel plus pegfilgrastim with stage IV non-small cell lung cancer patients
Acronym Phase II study of ramucirumab plus docetaxel plus pegfilgrastim with stage IV non-small cell lung cancer patients
Scientific Title Phase II study of ramucirumab plus docetaxel plus pegfilgrastim with stage IV non-small cell lung cancer patients
Scientific Title:Acronym Phase II study of ramucirumab plus docetaxel plus pegfilgrastim with stage IV non-small cell lung cancer patients
Region
Japan

Condition
Condition non-small cell lung cancer
Classification by specialty
Pneumology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To evaluate efficacy and safety of ramucirumab plus docetaxel plus pegfilgrastim in stage IV non-small cell lung cancer
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes incidence of febrile neutropenia
Key secondary outcomes Progression free survival
Overall Response Rate
Disease Control Rate
Overall Survival
Safety, Toxicity

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Addition of primary prophylaxis with pegfilgrastim to ramcirumab plus docetaxel treatment
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1.Histologically and/or cytologically proven non-small cell lung cancer
2.Patients who have previously treated with chemotherapy and have unresectable clinical stage IV or post-operative recurrence
3.Progression was observed during or after chemotherapy
4. More than twenty years old at the time of the agreement acquisition
5.ECOG Performace Status (PS) 0-1
6.Meets the following criteria
absolute neutrophil: >=1500/mm3
platelet count: >=100,000/mm3
hemoglobin: >=10.0 g/dL
AST and ALT: <=2.5 X ULN
total bilirubin: <=ULN
PT-INR: <=1.5
APTT: <=1.5 X ULN
protein urea: <=1+
7.Written informed consent to participate in this study
Key exclusion criteria 1. Symptomatic brain metastases
2. History of bleeding
3. Patient with HIV or HBV or HCV infection
4. Patient with active infection
5. Fever over 38
6. Patient with serious disease condition (severe heart disease, interstitial pneumonia, uncontrollable hypertension, diabetes mellitus, etc)
6. Severe complication (congestive heart failure, arrhythmia, uncontrollable hyper tension, uncontrollable diabetes)
7.Interstitial pneumonia , fibroid lung confirmed by CT.
8.Patient with much ascetic fluid, pleural effusion, cardiac effusion.
9. Patient with active double cancer. (Exclude disease free interval over 5 years and carcinoma in situ)
10. History of severe drug allergy
11.Patient with gastrointestinal perforation within 1 year.
12. Receiving anticoagulant therapy. (Aspirin 325mg or less to allow)
13. Patient thought as of high risk of bleeding (Obvious tumor invasion to main thoracic vessel and cavity) and of thromboembolizm.
14. History of docetaxel or ramcirumab treatment.
15. Considered as unfit to study drug administration by attending doctor according to clinical symptoms or laboratory abnormalities.
16. Considered to be interfere to the agreement or understanding the protocol by attening doctor.
17. Patient with impaired mental status.
18. Pregnancy
19. Other ineligible status judged by attending doctor.
Target sample size 20

Research contact person
Name of lead principal investigator
1st name Norimitsu
Middle name
Last name Kasahara
Organization Gunma University
Division name Department of Allergy and Respiratory Medicine
Zip code 371-8511
Address 3-39-15, Showa-machi, Maebashi, Gunma
TEL 027-220-7111
Email m14702016@gunma-u.ac.jp

Public contact
Name of contact person
1st name Norimitsu
Middle name
Last name Kasahara
Organization Gunma University
Division name Department of Allergy and Respiratory Medicine
Zip code 371-8511
Address 3-39-15, Showa-machi, Maebashi, Gunma
TEL 027-220-7111
Homepage URL
Email m14702016@gunma-u.ac.jp

Sponsor
Institute Gunma University
Institute
Department

Funding Source
Organization none
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Gunma Institutional Review Board
Address 3-39-15, Showa-machi, Maebashi, Gunma
Tel 027-220-7111
Email m14702016@gunma-u.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2017 Year 02 Month 10 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 20
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2017 Year 01 Month 26 Day
Date of IRB
2017 Year 01 Month 26 Day
Anticipated trial start date
2017 Year 02 Month 01 Day
Last follow-up date
2019 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2017 Year 02 Month 02 Day
Last modified on
2019 Year 08 Month 06 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029855

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.